摘要
Key points： PRATO-ACS randomized NSTE-ACS patients to rosuvastatin or control prior to PCI Statin resulted in significant decrease in nephropathy, better short-term outcomes Data needed to elucidate class effects of statins, causality
Key points： PRATO-ACS randomized NSTE-ACS patients to rosuvastatin or control prior to PCI Statin resulted in significant decrease in nephropathy, better short-term outcomes Data needed to elucidate class effects of statins, causality
